Filing expands Cellantra’s intellectual-property portfolio around reusable cell-surface address ligands and supports the G059/W2993 targeted mRNA-LNP co-lead program
Cellantrah, a preclinical in vivo gene-therapy biotechnology company developing precision-targeted medicines, today announced the filing of a patent application covering G059, the company’s proprietary surface-targeting ligand being developed as the address component of its second targeted mRNA-LNP co-lead program.
G059 is designed to recognize a selected, currently undisclosed cell-surface address associated with Cellantra’s colorectal cancer development strategy. The ligand is paired with W2993, the company’s lead intracellular KRAS G12D payload, in the G059/W2993 program.
Cellantra is developing G059/W2993 as a systemically administered targeted mRNA-LNP product concept for colorectal cancer, including colorectal liver metastases.
The patent filing is intended to strengthen Cellantra’s intellectual-property position around G059, its surface-targeting properties, and its application within targeted gene-delivery product architectures.
Building a Second Proprietary Address
Cellantra’s technology strategy separates two fundamental components of targeted gene delivery:
the address, which determines which cells or tissues the product is designed to recognize; and
the payload, which determines what biological activity is produced after successful intracellular delivery.
Under this framework, G059 functions as the extracellular address while W2993 provides the intracellular KRAS G12D-directed payload.
The G059 program gives Cellantra a second proprietary targeting asset distinct from A20T013 and allows the company to test whether a shared payload and delivery-development framework can be deployed across different tumor compartments and routes of administration.
Ally, Chief Operating Officer of Cellantra, commented:
“G059 represents more than a second development program. It represents a second proprietary address within the Cellantra platform. Our goal is to build a portfolio in which we own important components at multiple layers—the surface address, the intracellular payload and the integrated delivery architecture.”
“From an operating perspective, that creates meaningful leverage. We can carry forward what we learn about W2993, mRNA expression, formulation, analytics and product development while independently solving the biological-access problem for each new address. G059 gives us an opportunity to demonstrate that the platform can extend beyond a single ligand, route or tumor compartment.”
“Protecting G059 is therefore an important part of building the company. We are not simply assembling individual experiments; we are building a portfolio of proprietary assets that can support multiple products over time.”
G059/W2993: A Systemic Targeted-Delivery Program
The G059/W2993 program is designed around systemic delivery to address colorectal cancer and colorectal liver metastases.
In this product configuration:
G059 provides the surface address.
The ligand is intended to recognize the selected cell-surface target and support preferential product interaction with the intended tumor compartment.
The targeted LNP provides the delivery architecture.
The product is being engineered to transport an mRNA payload following systemic administration.
W2993 provides the intracellular payload.
Following productive delivery and expression, W2993 is intended to engage intracellular KRAS G12D.
The program has passed Cellantra’s company-defined preclinical stage gate and is progressing through confirmatory development work.
Upcoming work is expected to focus on native G059 binding, relevant selectivity, tumor-lesion accessibility, address-dependent cellular uptake, biodistribution, intracellular payload expression and integrated in vivo product performance.
Expanding the Address Portfolio
Cellantra believes proprietary surface-address ligands can form an important layer of a broader precision gene-delivery platform.
Rather than developing every therapeutic program from an entirely new architecture, the company seeks to reuse validated components and development methods where scientifically appropriate while preserving independent evidence requirements for each new product.
For example, W2993 is shared between the A20T013/W2993 and G059/W2993 co-lead programs. However, the two programs use distinct surface addresses and different delivery strategies for their intended disease compartments.
This structure allows payload-related knowledge to be shared while requiring each ligand and integrated product to independently demonstrate binding, accessibility, delivery, expression, function and safety.
The company believes this approach can create a growing library of proprietary addresses and payloads that may ultimately be combined into additional targeted therapeutic configurations.
Intellectual Property as a Core Platform Asset
The G059 patent filing follows Cellantra’s strategy of building intellectual property around the individual components that enable precision in vivo therapeutics.
The company is developing intellectual-property positions around:
- proprietary surface-address ligands;
- intracellular therapeutic payloads;
- targeted delivery architectures;
- ligand-display and product configurations;
- therapeutic applications; and
- integrated address-plus-payload products.
Cellantra intends to continue expanding this portfolio as its lead programs generate additional experimental evidence and new address-and-payload combinations enter development.
About Cellantra
The company is developing an address-plus-payload platform that combines proprietary cell-surface targeting ligands, gene-delivery technologies and disease-relevant intracellular payloads.
Cellantra’s two targeted mRNA-LNP co-lead programs are A20T013/W2993 and G059/W2993. The programs use distinct surface-address strategies while sharing W2993, the company’s lead intracellular KRAS G12D payload.
Beyond its co-lead programs, Cellantra is building a broader pipeline spanning additional KRAS-directed payloads, in vivo engineered-TCR programs, CAR-mRNA approaches and in vivo gene-editing concepts.
The company’s development strategy emphasizes modular intellectual property, experimentally validated targeting and disciplined integration of address, delivery, payload and route into product-specific therapeutic programs.
Media / Corporate Contact
Cellantra
[Name]
[Email]
[Website]
All Cellantra programs are investigational and preclinical. A company-defined preclinical stage-gate result does not establish clinical safety, efficacy, regulatory clearance or completion of IND-enabling studies. Statements regarding G059 targeting, delivery, future development, intellectual property and potential therapeutic applications are forward-looking and subject to scientific, intellectual-property, regulatory and development risks.
